Jivan and NimbleGen Partner for Splice Array Market
News Feb 03, 2006
"Jivan is proud to offer its full product line on NimbleGen's flexible and robust microarray platform," said Dr. Subha Srinivasan, CEO of Jivan Biologics (Berkeley, CA).
"This partnership furthers our goal to become the platform-independent solution for high-throughput splice variant analysis."
Dr. Stanley Rose, President and CEO of NimbleGen Systems (Madison, WI), commented, "Our collaboration with Jivan provides yet another example of an emerging measure of genome function or activity being enabled by NimbleGen’s platform."
"This product line nicely complements our whole genome ChIP-chip, CGH, Comparative Genome Sequencing, and Expression offerings, and further expands our integrated analytical capabilities also known as High Definition Genomics."
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018